| Company/Division name | Apertus Pharmaceuticals |
| Parent company | Apertus Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 9.5 |
| City reshored to: | St.Louis |
| State(s) reshored to: | MO |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | lomustine, a critical cancer medication |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Better Control of Process/Delivery/Factory, Eco-system synergies, Government Incentives |
